Clinical TrialMay 11, 2026, 04:07 PM
Pliant Therapeutics Doses First Patient in FORTIFY Phase 1b Trial
AI Summary
Pliant Therapeutics announced the dosing of the first participant in its FORTIFY Phase 1b indication expansion trial for PLN-101095, an oral dual selective inhibitor, ahead of schedule in April. The company also presented updated positive data from the Phase 1 trial of PLN-101095 at AACR 2026, showing deepening responses in checkpoint inhibitor-refractory solid tumors, leading to its spotlight in a plenary session. Concurrently, Pliant reported first quarter 2026 financial results, with a reduced net loss of $20.0 million, down from $56.2 million in the prior-year quarter, and a cash runway extending into the second half of 2028.
Key Highlights
- Pliant Therapeutics dosed the first participant in the FORTIFY Phase 1b indication expansion trial for PLN-101095 ahead of schedule in April.
- Updated Phase 1 data for PLN-101095 presented at AACR 2026 showed deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors.
- PLN-101095 was spotlighted as a novel IO approach at AACR's 2026 Highlights Plenary Session.
- Research and development expenses decreased to $13.6 million in Q1 2026 from $43.4 million in Q1 2025.
- General and administrative expenses decreased to $8.2 million in Q1 2026 from $15.5 million in Q1 2025.
- Net loss for Q1 2026 was $20.0 million, significantly lower than $56.2 million in Q1 2025.
- The company reported $172.4 million in cash, cash equivalents, and short-term investments as of March 31, 2026.
- Cash runway is expected to fund operations into the second half of 2028.